HIV Infection Clinical Trial
— PrEP-IndiaOfficial title:
Closing a Critical HIV Prevention Gap: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) as Part of an HIV Combination Preventive Intervention for Sex Workers in Kolkata and Mysore-Mandya, India
| Verified date | October 2016 |
| Source | University of Manitoba |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Female sex workers (FSWs) in India are at high risk of HIV infection, and while correct and
consistent condom use is an effective means of preventing HIV transmission, many FSWs have
difficulty insisting on their use. Alternative HIV prevention options are needed for FSWs who
are unable to correctly and consistently use condoms with their clients or regular partners.
Oral pre-exposure prophylaxis (PrEP) may be an important tool to fill this critical
prevention gap, and a demonstration project is required to assess the impact and feasibility
of the use of PrEP as an HIV prevention intervention among most at risk FSWs in India.
The proposed project will take place at two sites in India and will assess the use of a risk
assessment tool to identify FSWs who would most benefit from PrEP, collect information about
the reasons why FSWs choose to accept or decline PrEP, evaluate two different PrEP delivery
strategies (weekly clinic pick-up or home delivery by peer educators every second day),
monitor adherence to and discontinuation of PrEP, and evaluate unintended consequences of the
use of PrEP in these communities (e.g. reduction of condom use, drug side effects or adverse
events, social harms or resistance). To ensure the safety of study participants, a community
advisory board will be set up and will meet regularly to inform study staff of any concerns
that the community may have related to the study, so that the study staff can respond in a
timely manner. A data safety and monitoring board will also be established to monitor
participant safety.
| Status | Completed |
| Enrollment | 1325 |
| Est. completion date | June 30, 2018 |
| Est. primary completion date | April 30, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 49 Years |
| Eligibility |
Inclusion Criteria: - Self-identification as a current FSW - Age 18 and older - Self-reported interest in and willingness to take PrEP - Score cutoff on risk screening tool / PrEP indication tool - HIV-negative test at time of enrollment (per testing algorithm) - No clinical signs of acute HIV infection - Hepatitis-B virus antigen negative (upon screening) - Creatinine clearance = 60ml/min (Cockcroft-Gault formula) (upon screening) - Not currently taking PrEP or enrolled in another PrEP demonstration project - Negative urine pregnancy test at time of enrollment - Lives within the catchment area of the project site and no plans to move away from the project area in the next 16 months Exclusion Criteria: - Under 18 - Does not meet inclusion criteria |
| Country | Name | City | State |
|---|---|---|---|
| India | DMSC Clinic | Kolkata | West Bengal |
| India | Ashodaya Samithi clinic | Mysore | Karnataka |
| Lead Sponsor | Collaborator |
|---|---|
| University of Manitoba | Ashodaya Samithi, DMSC, World Health Organization |
India,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Sustained uptake and adherence to oral PrEP among female sex workers | We will assess the acceptability and feasibility of two approaches to PrEP delivery: 1) peer educator delivery every other day; or 2) weekly clinic pick-up. Study staff will measure PrEP initiation, adherence and discontinuation. They will record these events in participant records, and quarterly visits will be used to assess adherence through biological tests and questionnaires. PrEP will be delivered as part of a package of HIV prevention services, and therefore use of other prevention strategies, such as condom use, will also be monitored. Data on drug adherence and condom use will be collected through various means. An ethnographic study will be designed to understand factors that may promote or impede adherence to PrEP, as well as changes in risk behaviour (reduction in condom use). In addition to this, peer educators will use a pictorial tool to document these items (e.g., frequency and patterns of sexual activity, condom use, and PrEP use). | 24 months | |
| Secondary | Identification of female sex workers willing to take PrEP | We propose to develop and use of a risk screening tool to identify female sex workers who are most vulnerable to HIV. This tool will guide recruitment into the demonstration study and could later assist health providers in deciding who will benefit most from PrEP for HIV prevention. In addition, this study will assess the proportion of FSWs identified by the risk screening tool who are willing to take PrEP. Quantitative and qualitative evaluations will identify factors related to the decision to initiate PrEP as well as reasons why FSWs decline PrEP | 18 months after study commencement | |
| Secondary | Oral HIV PrEP as part of a combined prevention package delivered safely for female sex workers | The most common side effects of FTC/TDF are minor and short-lived (i.e. first several weeks). Quarterly clinic visits will assess physical health, side effects, adverse events and any other social harms or concerns with PrEP use. This study will invest in continuous engagement with communities of female sex workers according to good participatory practice guidelines to provide correct information about PrEP, keep communities continuously engaged, and maintain adherence to PrEP. A community advisory board (CAB) and a Data Safety and Monitoring Board (DSMB) will be set up. The CAB will meet monthly and on an as needed basis. The DSMB will be set up to ensure that the rights of the study participants are safeguarded in a transparent fashion, and to monitor their safety by scrutinizing any adverse events. | 24 months | |
| Secondary | Effective delivery of oral HIV PrEP demonstrated in context of National Targeted Interventions | This study proposes to deliver PrEP within the context of the National Program of Targeted Interventions in order to demonstrate that PrEP is feasible in "real world" settings. DMSC and Ashodaya currently implement targeted intervention programs for female sex workers in Kolkata and Mysore/Mandya, respectively. These programs provide outreach by peer educators and outreach workers, clinic services (e.g. HIV testing and counseling, STI screening and treatment), and referrals for HIV care and treatment for brothel- and street-based FSWs. This study will evaluate the addition of PrEP to this existing service delivery model. It will also show willingness of participants to enroll in a demonstration study and to use oral PrEP without reimbursements or incentives for participation. | 24 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
| Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
| Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
| Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
| Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
| Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
| Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
| Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
| Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
| Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
| Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
| Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
| Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
| Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
| Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
| Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
| Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
| Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
| Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
| Completed |
NCT01702974 -
Immune Reconstitution in HIV Disease (IREHIV)
|
Phase 2 |